Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams Abstract #2143

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Aim(s): To evaluate the response of IBI308 in treating advanced NENs and to find out the effective population by using several biomarkers.
Materials and methods: We had prospectively enrolled patients pathologically diagnosed as NENs after standard treatment failure to receive IBI308 treatment. Most of patients had received IBI308 200mg q3w. Response was assessed every 9 weeks.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1468 Evaluation of ENETS and AJCC Staging Systems for Pancreatic Neuroendocrine Neoplasms: A Multicenter Study in China.
Introduction: Accurate staging system is crucial for p-NENs management. The European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/ American Joint Cancer Committee/ World Health Organization (UICC/AJCC/WHO) advocated their TNM staging system for pancreatic neuroendocrine neoplasms (p-NENs) respectively.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr Kaizhou Jin
Authors: Jin K, Zhang Y, Luo G, Sun J, ...
#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors
Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Professor Zhongwu Li
Authors: Li Z, Leng J, Wang H, Li S, ...
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Zhang P, Qiu X D, Li X K, ...